HealthCare Global Enterprises Limited HCG NSEPHARMA
HealthCare Global Enterprises Limited provides medical and healthcare services in India and internationally. The company offers cancer diagnostics services, including genomics and molecular diagnostics, digital PET, preventive oncology, physical examination, laboratory tests, home health services, digital pathology, and CTC detection; treatment services, such as medical oncology and haemato-oncology, radiation and surgical oncology, molecular imaging and theranostics, chemotherapy, robotic surgery, actinium and lutetium therapy, immunotherapy, psycho-oncology, targeted drug therapy, bone marrow transplant, pediatric oncology, organ preservation and reconstructive surgery, endocrine therapy, and liver transplant; and post care services comprising patient care, psychological support, nutrition and dietetics, multidisciplinary rehabilitation, and genetic counselling. It also provides cancer screening, interventional radiology, MRI, nephrology, clinical trial, hormone therapy, hematology, CAR T cell, translational and nuclear medicine, oncodermatology, anaesthesiology, paediatric and gynaecologic oncology, orthopaedic oncology, uro-oncology, infectious diseases, gastrointestinal and thoracic oncology, breast surgical oncology, clinical pharmacology, and pain and palliative services. In addition, the company operates multi-specialty hospitals under the HCG brand that offers inpatient and outpatient treatments with specialties in cardiology, neurology, orthopaedics, gastroenterology, urology, internal medicine and pulmonary, and critical care. Further, it provides oncology diagnostics services, including biomarker and translational research, and clinical research services under the Triesta Sciences brand; and fertility treatment services, including reproductive medicine, assisted reproduction, gynecological endoscopy, and fertility preservation under the Milann brand. HealthCare Global Enterprises Limited was founded in 1989 and is headquartered in Bengaluru, India.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Compounding revenue at 14.8% over 5 years.
CONS
- Trading at a high P/E of 663.8.
- Earnings shrank at -22.3% CAGR over 5 years.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | HCG HealthCare Global Enterprises Limited NSEPHARMA | 637.25 | 663.80 | ₹9,514.28 Cr | - | 7.00% | 1.90% | 14.84% | -22.31% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,799.20 | 37.59 | ₹4.32 L Cr | 0.92% | 17.94% | 14.72% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 6,667.00 | 68.97 | ₹1.77 L Cr | 0.45% | 18.96% | 16.19% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,410.80 | 68.96 | ₹1.49 L Cr | 0.86% | 9.06% | 16.98% | 13.27% | 20.21% |
| 5 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,401.00 | 29.16 | ₹1.13 L Cr | 0.93% | 14.88% | 11.74% | 7.23% | 11.45% |
| 6 | DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA | 1,303.50 | 25.90 | ₹1.09 L Cr | 0.61% | 14.00% | 11.83% | 10.96% | -2.35% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,077.70 | 21.51 | ₹1.08 L Cr | 0.09% | 19.24% | 18.32% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,267.70 | 19.49 | ₹1.04 L Cr | 0.53% | 28.42% | 26.91% | 19.10% | 131.46% |
| 9 | MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA | 2,375.60 | 51.29 | ₹98,090.71 Cr | 0.08% | 13.78% | 12.45% | 17.73% | 14.28% |
Quarterly Results
Figures in INR.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 583.43 Cr | 611.80 Cr | 645.16 Cr | 631.18 Cr | 650.29 Cr |
| Cost of Revenue | 283.23 Cr | 294.89 Cr | 313.75 Cr | 315.69 Cr | 317.04 Cr |
| Gross Profit | 300.20 Cr | 316.91 Cr | 331.41 Cr | 315.49 Cr | 333.25 Cr |
| Operating Expenses | 252.55 Cr | 267.03 Cr | 270.90 Cr | 266.53 Cr | 270.98 Cr |
| Operating Income | 47.65 Cr | 49.88 Cr | 60.51 Cr | 48.96 Cr | 62.27 Cr |
| EBITDA | 115.86 Cr | 115.30 Cr | 126.24 Cr | 99.36 Cr | 106.76 Cr |
| Interest Expense | 44.17 Cr | 45.47 Cr | 43.62 Cr | 44.78 Cr | 42.70 Cr |
| Pretax Income | 13.62 Cr | 11.92 Cr | 19.82 Cr | -6.07 Cr | 1.25 Cr |
| Tax Provision | 6.85 Cr | 5.94 Cr | -84.00 L | 1.83 Cr | -2.79 Cr |
| Net Income | 7.36 Cr | 4.75 Cr | 16.27 Cr | -9.43 Cr | 2.17 Cr |
| Diluted EPS | 0.52 | 0.34 | 1.15 | -0.68 | 0.15 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 1,676.05 Cr | 1,889.91 Cr | 2,218.14 Cr | 2,538.43 Cr |
| Cost of Revenue | - | 799.75 Cr | 909.99 Cr | 1,062.27 Cr | 1,241.37 Cr |
| Gross Profit | - | 876.29 Cr | 979.92 Cr | 1,155.87 Cr | 1,297.06 Cr |
| Operating Expenses | - | 708.04 Cr | 822.48 Cr | 979.93 Cr | 1,075.44 Cr |
| Operating Income | - | 168.25 Cr | 157.44 Cr | 175.94 Cr | 221.62 Cr |
| EBITDA | - | 302.75 Cr | 342.78 Cr | 422.86 Cr | 447.66 Cr |
| Interest Expense | - | 94.39 Cr | 100.69 Cr | 154.56 Cr | 176.57 Cr |
| Pretax Income | - | 44.88 Cr | 67.73 Cr | 56.96 Cr | 26.92 Cr |
| Tax Provision | - | 27.25 Cr | 26.39 Cr | 8.13 Cr | 4.14 Cr |
| Net Income | - | 29.35 Cr | 48.16 Cr | 44.41 Cr | 13.76 Cr |
| Diluted EPS | - | 2.09 | 3.41 | 3.12 | 0.96 |
Compounded Sales Growth
| 5 Years: | 14.84% |
| 1 Year: | 11.50% |
Compounded Profit Growth
| 5 Years: | -22.31% |
| 1 Year: | -71.20% |
Stock Price Performance
| 1 Year: | +18.14% |
| 6 Months: | -12.24% |
| 3 Months: | +9.66% |
| 1 Month: | +11.30% |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 2,316.02 Cr | 2,707.50 Cr | 3,543.24 Cr | 3,922.54 Cr |
| Current Assets | - | 580.34 Cr | 679.85 Cr | 843.80 Cr | 1,135.21 Cr |
| Cash & Equivalents | - | 174.62 Cr | 272.61 Cr | 235.87 Cr | 536.05 Cr |
| Inventory | - | 38.29 Cr | 42.67 Cr | 53.02 Cr | 59.82 Cr |
| Receivables | - | 302.51 Cr | 294.03 Cr | 400.90 Cr | 420.70 Cr |
| Total Liabilities | - | 1,446.60 Cr | 1,842.38 Cr | 2,553.19 Cr | 2,512.33 Cr |
| Current Liabilities | - | 570.32 Cr | 743.71 Cr | 1,046.42 Cr | 1,017.16 Cr |
| Long Term Debt | - | 361.74 Cr | 485.30 Cr | 604.58 Cr | 599.19 Cr |
| Total Debt | - | 901.20 Cr | 1,274.36 Cr | 1,837.22 Cr | 1,735.36 Cr |
| Total Equity | - | 860.52 Cr | 825.78 Cr | 922.44 Cr | 1,331.97 Cr |
| Shares Outstanding | - | 14.00 Cr | 14.02 Cr | 14.03 Cr | 14.93 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 251.59 Cr | 284.58 Cr | 317.11 Cr | 347.10 Cr |
| Investing Cash Flow | - | -133.03 Cr | -225.73 Cr | -487.75 Cr | -177.47 Cr |
| Financing Cash Flow | - | -140.07 Cr | -64.02 Cr | -42.44 Cr | 240.67 Cr |
| Capital Expenditure | - | -133.24 Cr | -185.68 Cr | -208.87 Cr | -292.10 Cr |
| Free Cash Flow | - | 118.35 Cr | 98.90 Cr | 108.24 Cr | 55.00 Cr |
| Net Change in Cash | - | -21.51 Cr | -5.16 Cr | -213.08 Cr | 410.30 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 52.3% | 51.9% | 52.1% | 51.1% |
| Operating Margin % | - | 10.0% | 8.3% | 7.9% | 8.7% |
| Net Margin % | - | 1.8% | 2.5% | 2.0% | 0.5% |
| ROE % | - | 3.4% | 5.8% | 4.8% | 1.0% |
| ROCE % | - | 9.6% | 8.0% | 7.0% | 7.6% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HCG